About Cellerant

Cellerant Therapeutics is a privately-held, clinical-stage biotechnology company with a portfolio of novel innate and adaptive immunotherapies for oncology and blood-related disorders, including cell-based and antibody therapeutics. Cellerant's lead product, CLT-008, is a myeloid progenitor cell therapy currently in Phase 2 clinical development in patients with acute myeloid leukemia (AML). The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for AML, multiple myeloma and myelodysplastic syndrome.

Cellerant News & Press Releases

May 17, 2018
Pinkal Desai | EHA 2018 | CLT008 reduces serious infections, antibiotic use and days of hospitalization during AML induction

July 2, 2018
CELLERANT THERAPEUTICS, INC. ANNOUNCES FDA GRANTS

June 18, 2018
CELLERANT THERAPEUTICS, INC. PRESENTS PHASE 2 RESULTS

June 24, 2018
CELLERANT THERAPEUTICS, INC. CLT-008 PHASE 2 RESULTS SHOW SIGNIFICANT REDUCTION IN INFECTIONS AND DAYS IN HOSPITAL

more >

Copyright ©2006-2018 Cellerant Therapeutics, Inc.